By combining an FDA-approved cancer immunotherapy with an emerging tumor-roasting nanotechnology, researchers improved the efficacy of both therapies in a proof-of-concept study using mice. The potent combination also attacked satellite tumors and distant cancerous cells, completely curing two mice and effectively vaccinating one against the disease.